Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 4/20 | 0.46 |
| ▸ | F2 | P00734 | 1/20 | 0.46 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.46 |
| ▸ | SRC | P12931 | 6/20 | 0.44 |
| ▸ | NPY1R | P25929 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | CASP3 | P42574 | 1/20 | 0.41 |
| ▸ | APP | P05067 | 1/20 | 0.39 |
| ▸ | MME | P08473 | 1/20 | 0.39 |
| ▸ | ACE | P12821 | 1/20 | 0.39 |
| ▸ | XIAP | P98170 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5639237 | 0.85 | NPY1R (0.50) | F10SRCNPY1RAPPMME | |
| SCHEMBL12527914 | 0.85 | KMT2A (0.55) | F10F2PRSS1SRCNPY1R | |
| SCHEMBL12527916 | 0.84 | KMT2A (0.54) | F10F2PRSS1SRCNPY1R | |
| SCHEMBL4196013 | 0.82 | NPY1R (0.51) | F10F2PRSS1SRCNPY1R | |
| SCHEMBL13904759 | 0.82 | NPY1R (0.51) | F10F2PRSS1SRCNPY1R | |
| SCHEMBL13904769 | 0.82 | NPY1R (0.53) | F10SRCNPY1RAPP | |
| SCHEMBL13818354 | 0.81 | SRC (0.61) | SRCKMT2AL3MBTL1 | |
| SCHEMBL14859419 | 0.81 | F2 (0.45) | F10F2PRSS1SRCKMT2A | |
| SCHEMBL21165916 | 0.81 | F2 (0.53) | F10F2PRSS1SRCKMT2A | |
| SCHEMBL12525774 | 0.80 | KDM4E (0.47) | F10F2PRSS1SRCNPY1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040072818-A1 | Substituted quinoline CCR5 receptor antagonists | SCHERING AKTIENGESELLSCHAFT (DE) | 2004-04-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040072818-A1 | Substituted quinoline CCR5 receptor antagonists | CCR5, CXCR3, CCR2 | F10 4667/4885F2 4543/4885PRSS1 1278/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.